Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ClearPoint Neuro Inc (CLPT) vs Nasdaq Inc (NDAQ) Price & Performance

ClearPoint Neuro IncTrade
Nasdaq IncTrade

Price performance (Past 24H)

Key statistics

ClearPoint Neuro Inc vs Nasdaq Inc — how do they compare? ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M), while Nasdaq Inc trades at $95.85 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 116.9× ClearPoint Neuro Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

CLPTNDAQ
Market Cap
$454.21M$53.11B
Sector
HealthFinancials
52-Week High
$29.60$100.98
52-Week Low
$8.66$76.85
Enterprise Value
$488.79M$59.57B
Dividend Yield
1.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.

The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.

Nasdaq Inc

Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.

The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

Read more on NDAQ